165 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials
8-K
EX-99.1
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy
8-K
EX-99.1
0e20f7a3p
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
EX-99.1
due2o
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
EX-99.1
6t9yqawoj3ieg9p94
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
EX-99.1
ze4 hfywk68k7cd4
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-99.1
j9eo45z8
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
mj8uy 7jld3q8
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
9mh7k 9l3
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-99.1
1wzcnodnexpl1jjzg9s
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
xqrnx9q6vzb1gcd
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
DEFA14A
l4l zl9409n0e
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
EX-99.1
tn6lttkgsmdt
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm